Suggestions
Karsten Miermans
improving clinical cytometry with machine learning | hema.to co-founder
Karsten Miermans, CEO and Co-founder of hema.to
Karsten Miermans is the CEO and co-founder of hema.to, a Munich-based health tech startup bringing AI automation to the clinical analysis of blood data.123457 He has a background in biophysics, software development, data science and entrepreneurship.5
Miermans co-founded hema.to in 2021 with the mission to make clinical analysis of cytometry data completely objective and enable doctors to personalize treatment to their patient's unique immune system.1 The company has developed a breakthrough AI-powered diagnostic platform for leukemia and lymphoma that is already in routine use by leading hematology laboratories.3
Under Miermans' leadership, hema.to recently raised a €3.6 million seed funding round from investors including Elaia Partners, Heal Capital, and High-Tech Gründerfonds (HTGF).12 The funds will allow the company to grow its team of software engineers and immunologists, and scale its AI capabilities.2
Miermans is passionate about improving cytometry and blood diagnostics to advance precision immune medicine.4 He frequently speaks about hema.to's mission and technology at industry events.6
